Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
31682877
DOI
10.1016/j.jinf.2019.10.018
PII: S0163-4453(19)30332-9
Knihovny.cz E-zdroje
- Klíčová slova
- Antibiotic resistance, Bacterial meningitis, Conjugate vaccine, Eastern Europe, High-risk groups, Immunization program, Meningococcal disease, Neisseria meningitidis, Polysaccharide vaccine, Refugees,
- MeSH
- epidemický výskyt choroby * MeSH
- incidence MeSH
- kontrola infekčních nemocí organizace a řízení MeSH
- lidé MeSH
- meningokokové infekce epidemiologie mikrobiologie prevence a kontrola MeSH
- meningokokové vakcíny aplikace a dávkování imunologie MeSH
- Neisseria meningitidis klasifikace izolace a purifikace MeSH
- přenašečství epidemiologie mikrobiologie prevence a kontrola MeSH
- přenos infekční nemoci prevence a kontrola MeSH
- séroskupina MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- východní Evropa epidemiologie MeSH
- Názvy látek
- meningokokové vakcíny MeSH
The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,000 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended.
Baku Medical Plaza Baku Azerbaijan
Cantacuzino National Medico Military Institute for Research Development Bucharest Romania
Central Research Institute of Epidemiology Moscow Russia
Eskisehir Osmangazi University Eskisehir Turkey
Institute for Public Health Sombor Serbia
Institute of Health Carlos 3 Madrid Spain
Kazakh National Medical University Almaty Kazakhstan
Meningitis Research Foundation Bristol UK
Meningococcal Reference Unit Public Health England Manchester Royal Infirmary Manchester M13 9WZ UK
National Center for Disease Control and Public Health Tbilisi Georgia
National Institute of Public Health Prague Czechia
National Public Health Center Budapest Hungary
National Reference Centre for Bacterial Meningitis National Medicines Institute Warsaw Poland
National Reference Centre for Meningococci Institute Pasteur Paris France
Norwegian Institute of Public Health Oslo Norway
Republican Research and Practical Center for Epidemiology and Microbiology Minsk Belarus
Riga East University Hospital Riga Latvia
Scientific and Production Association Preventive Medicine Bishkek Kyrgyzstan
The Centre for Disease Prevention and Control of Latvia Riga Latvia
Citace poskytuje Crossref.org
